When Coverage Fails, So Does the “Script = Fill” Assumption

Pharma still models success as a linear funnel: diagnosis → prescription → fulfillment. However, this simplified model fails to account for the complexities of real-world scenarios. The moment a payer rejects coverage, that model breaks, revealing a chasm in the expected workflow. The subsequent fallout can impact not only the patient’s treatment journey but also the overall efficacy of the healthcare system. So what actually happens when insurers yield their power to deny coverage of a branded drug? This denial prompts a cascade of effects, including increased out-of-pocket costs for patients, the need for alternative therapies, and often, patients being forced to navigate a labyrinth of appeals and prior authorizations. Such obstructions can lead to delays in treatment, potentially compromising patient outcomes and raising broader ethical questions about access to necessary medications in an increasingly complex healthcare landscape.

When a close relative discussed his high cholesterol with his doctor, the physician recommended a new drug specifically designed to effectively treat his problem. This new medication promised to tackle his high cholesterol in a way that generics had failed to do, potentially leading to significant health improvements. However, the problem arose when his insurer denied coverage for this essential treatment, insisting he continue using generics despite his prior lack of response to them. This disappointing turn of events highlighted a growing concern among patients: they are beginning to realize that their insurer is not necessarily there to serve their healthcare needs or prioritize their well-being, but rather to safeguard its profits and minimize expenses. Such realizations can lead to feelings of frustration and helplessness among patients who are left navigating a system that often prioritizes cost-cutting over patient care and health outcomes.

1. Abandonment Is the Default Outcome

Multiple studies show that 20–30% of new prescriptions are never filled, and cost is the number one reason. When out-of-pocket costs exceed ~$100, abandonment rates can jump to 40–60%, depending on the therapeutic category.

This isn’t a motivation problem. It’s math.

Patients aren’t weighing clinical nuance—they’re asking:
“Can I afford this right now?”

2. Patients Ask for Alternatives (Even If They’re Inferior)

Roughly 30–50% of patients will return to their physician to request a covered alternative.

This creates a quiet but massive issue:

  • The prescribed drug may be clinically optimal
  • The dispensed drug is financially tolerable

Those are not the same thing—and outcomes suffer as a result.

3. Step Therapy and Prior Auth Kill Momentum

Even when patients try to push forward, payer controls get in the way:

  • Prior authorization approval rates vary widely, but delays can stretch from days to weeks
  • Step therapy forces patients onto older or less effective treatments first

Data shows that treatment drop-off increases significantly with each added administrative step. Every delay is another opportunity for the patient to disengage entirely.

4. Patients Hunt for Workarounds

This is where behavior gets messy—and revealing:

  • Manufacturer copay cards and patient assistance programs
  • Discount platforms like GoodRx
  • Pharmacy shopping (yes, patients will call or visit multiple locations)

But here’s the catch: awareness is inconsistent. Many patients never discover these options, and others give up midway through the process.

5. Some Patients Delay or Go Without

A meaningful percentage simply…wait.

  • They postpone treatment
  • Split pills or reduce dosage
  • Or abandon therapy altogether

In chronic conditions, this leads to worsening outcomes—and often higher downstream costs for the system.

6. The Rise of “Alternative Channels.”

Patients are increasingly turning to:

  • Online pharmacies (domestic and international)
  • Telehealth platforms offering bundled pricing
  • Patient communities sharing sourcing strategies

This is the part of the ecosystem pharma, and payers have the least visibility into—and the least control over.

What This Means for Pharma Marketers

If you’re still measuring success based on prescriptions written, you’re missing the point.

The real funnel looks more like this:

Awareness → Consideration → Prescription → Coverage Shock → Friction → Drop-off or Workaround

That “coverage shock” moment is where brands lose patients.

And yet, most marketing strategies are completely absent at this stage.

The Strategic Miss

Pharma spends billions to drive patients into doctors’ offices, asking for specific brands. But when access fails:

  • There’s no coordinated support experience
  • No real-time education about affordability options
  • No integration with the patient’s actual financial reality

In other words, the system creates demand it cannot fulfill.

The Opportunity

The brands that win won’t be the ones with the loudest DTC ads. They’ll be the ones that:

  • Anticipate coverage barriers before they happen
  • Equip physicians with clear, fast access pathways
  • Build patient support ecosystems that are actually usable
  • Treat affordability as part of the product—not an afterthought

Because in today’s market, clinical efficacy alone isn’t enough.

If the patient can’t access the drug, the drug doesn’t exist.

About Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

View all posts by Richard Meyer →

Leave a Reply